常山药业：艾本那肽注射液临床试验获批

Core Viewpoint - The company Changshan Pharmaceutical has received approval from the National Medical Products Administration for a clinical trial of its drug, Aibennatide injection, aimed at weight loss indications [1] Group 1: Company Developments - Changshan Pharmaceutical and its subsidiary, Changshan Kaijie Jian Biological Pharmaceutical Research (Hebei) Co., Ltd., have jointly submitted a clinical trial application for Aibennatide injection, which has now been approved [1] - Aibennatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) that is developed using DACTM technology, chemically modifying Exenatide and combining it with recombinant human serum albumin to form a new stable compound [1] Group 2: Drug Mechanism and Benefits - GLP-1RA works by activating the GLP-1 receptor in a glucose concentration-dependent manner, stimulating insulin secretion and suppressing glucagon secretion [1] - The drug also increases glucose uptake in muscle and fat tissues, inhibits hepatic glucose production, suppresses gastric emptying, and reduces appetite, thereby exerting its hypoglycemic effects [1]